Tamarit María del Palacio, Quereda Carmen, Gonzalez-Rozas Marta, Corral Iñigo, Casado José L
Department of Infectious Diseases, Ramón y Cajal Hospital, IRYCIS, Madrid, Spain.
AIDS Res Hum Retroviruses. 2012 Jan;28(1):83-6. doi: 10.1089/AID.2011.0020. Epub 2011 May 21.
HIV-1 viral encephalitis produced by antiretroviral-resistant strains in cerebrospinal fluid (CSF), despite suppression of plasma HIV-1 RNA, has been rarely described. We report two cases of symptomatic viral encephalitis demonstrated by clinical, magnetic resonance imaging (MRI), and an inflammatory CSF profile. Viral load in CSF was 24,000 and 6850 copies/ml, whereas plasma HIV RNA level was undetectable since the beginning of therapy. A resistance test in CSF showed genotypic mutations confering resistance to the drugs the patients received for more than 2 years. In the two cases, a high baseline HIV RNA level, a low nadir CD4(+) count, and suboptimal CSF levels of atazanavir were considered as the risk factors for developing encephalitis. The two cases did not resolve with a change to antiretroviral drugs with better CNS penetration, but they had complete clinical and MRI recovery after changing to therapy considering both CNS viral resistance and penetration.
尽管血浆中HIV-1 RNA受到抑制,但脑脊液(CSF)中抗逆转录病毒耐药株引起的HIV-1病毒性脑炎却鲜有报道。我们报告了两例有症状的病毒性脑炎病例,通过临床、磁共振成像(MRI)及脑脊液炎症指标得以证实。脑脊液中的病毒载量分别为24,000拷贝/毫升和6850拷贝/毫升,而自治疗开始以来血浆HIV RNA水平一直检测不到。脑脊液耐药检测显示存在基因变异,对患者已接受两年多的药物产生耐药。在这两例病例中,高基线HIV RNA水平、低最低点CD4(+)计数以及阿扎那韦脑脊液水平欠佳被认为是发生脑炎的危险因素。这两例病例在更换为中枢神经系统穿透性更好的抗逆转录病毒药物后并未好转,但在考虑中枢神经系统病毒耐药性和穿透性后更换治疗方案,临床和MRI均完全恢复。